GlaxoSmithKline: Carcinoma, Renal Cell trials
The registry lists 21 Carcinoma, Renal Cell studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 1 10Phase 2 4Phase 3 2No phase 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid TumorsCompletedNCT03693612Phase 1/2Results posted
- Cancer in Patients With Gabapentin (GPRD)CompletedNCT01236053Results posted
- Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)CompletedNCT01138124Results posted
- A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)CompletedNCT00726323Phase 2Results posted
- Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell CancerCompletedNCT00387764Phase 3Results posted
- Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell CarcinomaCompletedNCT00334282Phase 3Results posted
- GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell CarcinomaCompletedNCT00244764Phase 2Results posted
- First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruitingNCT05277051Phase 1
- Hepatic Monitoring for PazopanibCompletedNCT01449825
- Cardiovascular and Torsades de Pointes Monitoring for PazopanibCompletedNCT01446224
- Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)CompletedNCT01381614
- Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)CompletedNCT01381601
- An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell CarcinomaCompletedNCT00992121Phase 1
- VEG111485: A QTc Study of PazopanibCompletedNCT00861029Phase 1
- Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid TumorsCompletedNCT00516672Phase 1
- Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034CompletedNCT00478725Phase 1
- A Study To Test The Effect Of GW786034 (Pazopanib) On P450 EnzymesCompletedNCT00401583Phase 1
- A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer PatientsCompletedNCT00363194Phase 1
- Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple MyelomaCompletedNCT00256880Phase 2
- Oral Topotecan As A Radiosensitizing Agent In Rectal CancerTerminatedNCT00158886Phase 1
- Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer PatientsCompletedNCT00158782Phase 1